ArticleMedComm2026

Safety and Efficacy of Lucitanib Plus Toripalimab in Advanced Solid Tumors Refractory to Standard Therapies: An Open-Label, Multicenter, Phase II Study.

Ting Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.